Voxelotor is a first-in-class, reversible covalent aldehyde drug that prevents the hemoglobin polymerization, a primary driver of sickle cell disease. Approved in 2019 , this molecule represented a scientific milestone as a modern example of a reversible covalent drug being approved in a chronic indication. It is the first oral drug that [...]
1 minute read
Mar. 14, 2023
Voxelotor: a First-In-Class, Reversible Covalent Aldehyde Drug
GBT/Pfizer HbS polymerization inhibitor
FIC, oral, QD, reversible covalent HbS pol. inhibitor accelerated FDA approval for hemolytic anemia in SCD opt. + SBDD of natural product (5HMF) analogs voxelotor (GBT440, OXBRYTA) Global Blood Therapeutics, SSF, CA / Pfizer, NY